Literature DB >> 24389428

Beneath the blood brain barrier: the challenge of diagnosis and management of central nervous system involvement in ALK-positive lung cancer.

Rafal Dziadziuszko1, Jacek Jassem.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24389428     DOI: 10.1097/JTO.0000000000000054

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  1 in total

Review 1.  Alectinib: a review of its use in advanced ALK-rearranged non-small cell lung cancer.

Authors:  Kate McKeage
Journal:  Drugs       Date:  2015-01       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.